A novel mutation in the POLE2 gene causing combined immunodeficiency.

Authors:

Francesco Frugoni Kerry Dobbs Kerstin Felgentreff Hasan Aldhekri Bandar K Al Saud Rand Arnaout Afshan Ashraf Ali Avinash Abhyankar Fayhan Alroqi Silvia Giliani Mayra Martinez Ojeda Erdyni Tsitsikov Sung-Yun Pai Jean Laurent Casanova Luigi D Notarangelo John P Manis

J Allergy Clin Immunol 2016 Feb 11;137(2):635-638.e1. Epub 2015 Sep 11.

Department of Laboratory Medicine, Boston Children's Hospital, Boston, Mass; Department of Laboratory Medicine, Joint Program in Transfusion Medicine, Boston Children's Hospital, Boston, Mass; Department of Pathology, Harvard Medical School, Boston, Mass. Electronic address:

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jaci.2015.06.049	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747780	PMC

February 2016

Publication Analysis

Top Keywords

pole2 gene causing

mutation pole2

combined immunodeficiency

gene causing combined

Similar Publications

SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.

Authors:

Enze Liu Zhuang Zhuang Zhang Xiaolin Cheng Xiaoqi Liu Lijun Cheng

BMC Med Genomics 2020 04 3;13(Suppl 5):50. Epub 2020 Apr 3.

Department of Biomedical informatics, College of medicine, the Ohio State University, Columbus, OH, 43210, USA.

Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy. Due to its wide heterogeneity, PDAC acts aggressively and responds poorly to most chemotherapies, causing an urgent need for the development of new therapeutic strategies. Cell lines have been used as the foundation for drug development and disease modeling. Read More

View Article and Full-Text PDF

April 2020

Similar Publications